Restore Secures Another Clinical Trial with Ironshore

Tuesday, August 4, 2015 | 09:57 AM
Ironshore Pharmaceuticals & Development, Inc. ("Ironshore") has signed an agreement with Restore Health, a company specializing in personalized medicine, to participate in the fulfillment of a double-blind clinical trial, designed to evaluate the safety and efficacy of HLD-200, a new drug in development to treat Attention-deficit/hyperactivity disorder (ADHD). This is Restore's second clinical trial program with Ironshore.
Continue reading

Restore Health's Metabolic Supplement

Monday, August 3, 2015 | 01:42 PM
90% of the American population is vitamin deficient because of poor food quality; lack of access to readily available antioxidant-dense, clean organic fruits and vegetables; and vitamin depletion from medications, alcohol, and environmental toxins.
Continue reading
Restore Health, a company specializing in personalized medicine, announced today that its specialty pharmacy division is in the process of seeking accreditation from URAC, a Washington, D.C.-based healthcare accrediting organization that establishes quality standards for the healthcare industry.
Continue reading
Search Blog